New combo vaccine for kids could replace current shot

NCT ID NCT07406360

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study tests a new vaccine that protects against measles, mumps, rubella, and chickenpox (MMRV) in healthy children aged 15 months to 6 years. It compares the new vaccine to an already approved one (ProQuad) to see if it works as well and is safe. About 1,200 children will receive a second dose of either vaccine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Investigational measles, mumps, rubella, and varicella vaccine (MMRVNS)
What this could lead to: If successful, this could provide a safe and effective alternative to the current MMRV vaccine for children.
What could go wrong: This is a phase 3 trial, but it is not yet recruiting. The new vaccine may not be as effective or safe as the existing one, and results may not apply to all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chickenpox prevention target measles prevention target mumps infectious disease prevention target rubella prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEASLES MEASLES-MUMPS-RUBELLA+CHICKENPOX VACCINE

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Birmingham, Alabama, 35235, United States
GSK Investigational Site
RECRUITING

Walnut Creek, California, 94598, United States
GSK Investigational Site
RECRUITING

Miami, Florida, 33142, United States
GSK Investigational Site
RECRUITING

Miami, Florida, 33182, United States
GSK Investigational Site
RECRUITING

Atlanta, Georgia, 30310, United States
GSK Investigational Site
RECRUITING

Chicago, Illinois, 60621, United States
GSK Investigational Site
RECRUITING

Farmington Hills, Michigan, 48334, United States
GSK Investigational Site
RECRUITING

Dayton, Ohio, 45406, United States
GSK Investigational Site
RECRUITING

Simpsonville, South Carolina, 29680, United States
GSK Investigational Site
RECRUITING

Spartanburg, South Carolina, 29301, United States
GSK Investigational Site
RECRUITING

Frisco, Texas, 75033, United States
GSK Investigational Site
RECRUITING

Houston, Texas, 77065, United States
GSK Investigational Site
RECRUITING

Houston, Texas, 77077, United States
GSK Investigational Site
RECRUITING

Port Lavaca, Texas, 77979, United States
GSK Investigational Site
RECRUITING

Richmond, Texas, 77469, United States
GSK Investigational Site
RECRUITING

Provo, Utah, 84604, United States
GSK Investigational Site
RECRUITING

Richmond, Virginia, 23294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.